PROTEIN POLYMER TECHNOLOGIES ANNOUNCES RETIREMENT OF
J. THOMAS PARMETER, CHAIRMAN OF THE BOARD OF DIRECTORS
SAN DIEGO, APRIL 28 -- Protein Polymer Technologies, Inc. (OTC Bulletin Board:
PPTI.OB), a biotechnology device company that is a pioneer in protein design
and synthesis, today announced that its founder and Chairman of the Board
of Directors, J. Thomas Parmeter, Ph.D., is retiring, effective April 30,
2006. Dr. Parmeter will continue to serve as a consultant to the company.
PPTI’s Chief Executive Officer, William N. Plamondon III, will assume
the role of Chairman of the Board of Directors.
Dr. Parmeter, 66, has been Protein Polymer Technologies’ Chairman of
the Board of Directors since its inception in July 1988, and its President
and Chief Executive Officer until April 2005. From 1982 to November 1987, Dr.
Parmeter was the President, Chief Executive Officer (and, from 1987 to 1988,
Chairman of the Board) of Syntro Corporation, a San Diego-based biotechnology
company focused on recombinant vaccine development. Prior to joining Syntro,
Dr. Parmeter was a founder and Executive Vice President of Professional Health
Technologies, Inc. He was formerly an Associate Professor at Michigan State
University's College of Human Medicine, and Director of the College's Office
of Education and Interdepartmental Programs. Dr. Parmeter earned an M.Sc. in
management from Massachusetts Institute of Technology Sloan School of Management,
where he was an Alfred P. Sloan Fellow. He also holds a Ph.D. in Educational
Psychology from Michigan State University. He and his wife, Dr. Elizabeth Parmeter,
reside in La Jolla, California.
To schedule media interviews or
request product images, please contact Bryan deCastro
or Carole Boucard.
Contacts
Investor Contact:
Erin Davis
Director of Communications and Investor Relations
Protein Polymer Technologies, Inc.
(858) 558-6064 x 120
edavis@ppti.com |
Media Contact:
Bryan deCastro, (631) 495-9177
Carole Boucard, (954) 370-2524
Creative Public Relations
|
About
Protein Polymer Technologies
Protein Polymer Technologies, Inc. is a biotechnology company that discovers
and develops innovative therapeutic devices to improve medical and surgical
outcomes. The Company focuses on developing technology and products to be used
for soft tissue augmentation, tissue adhesives and sealants, wound healing
support and drug delivery devices. Protein Polymer Technologies’ proprietary
protein-based biomaterials are uniquely tailored to optimize clinical performance
and contain no human or animal components that could potentially transmit or
cause disease. The Company is headquartered in San Diego, California. For additional
information about the Company, please visit www.ppti.com.
To date, PPTI has been issued twenty-six U.S. patents on its core technology
with corresponding issued and pending patents in key international markets.
Safe Harbor
This press release contains forward-looking
statements that are based on management’s views
and expectations. Actual results could differ materially
from those expressed here; further, the Company is
not obligated to comment specifically on those differences.
Risks associated with the Company’s activities
include raising adequate capital to continue operations,
scientific and product development uncertainties,
competitive products and approaches, continuing collaborative
partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up. The reader
is encouraged to refer to the Company’s 2004
Annual Report Form 10-KSB, and 10KSB/A and other
recent filings with the Securities and Exchange Commission,
copies of
which are available from the Company, to further ascertain
the risks associated with the above statements.
